BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 12901972)

  • 1. Clinical relevance of CD95 (Fas/Apo-1) on T cells of patients with B-cell chronic lymphocytic leukemia.
    Groneberg C; Pickartz T; Binder A; Ringel F; Srock S; Sieber T; Schoeler D; Schriever F
    Exp Hematol; 2003 Aug; 31(8):682-5. PubMed ID: 12901972
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential sensitivity of CD4+ and CD8+ T lymphocytes to the killing efficacy of Fas (Apo-1/CD95) ligand+ tumor cells in B chronic lymphocytic leukemia.
    Tinhofer I; Marschitz I; Kos M; Henn T; Egle A; Villunger A; Greil R
    Blood; 1998 Jun; 91(11):4273-81. PubMed ID: 9596676
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Humoral immunodeficiency in chronic lymphocytic leukemia: role of CD95/CD95L in tumoral damage and escape.
    Sampalo A; Brieva JA
    Leuk Lymphoma; 2002 Apr; 43(4):881-4. PubMed ID: 12153179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Downregulation of the CD95 receptor and defect CD40-mediated signal transduction in B-chronic lymphocytic leukemia cells.
    Laytragoon-Lewin N; Duhony E; Bai XF; Mellstedt H
    Eur J Haematol; 1998 Oct; 61(4):266-71. PubMed ID: 9820634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of preactivated autologous T lymphocytes on CD80, CD86 and CD95 expression by chronic lymphocytic leukemia B cells.
    Romano C; De Fanis U; Sellitto A; Dalla Mora L; Chiurazzi F; Giunta R; Rotoli B; Lucivero G
    Leuk Lymphoma; 2003 Nov; 44(11):1963-71. PubMed ID: 14738151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Latent sensitivity to Fas-mediated apoptosis after CD40 ligation may explain activity of CD154 gene therapy in chronic lymphocytic leukemia.
    Chu P; Deforce D; Pedersen IM; Kim Y; Kitada S; Reed JC; Kipps TJ
    Proc Natl Acad Sci U S A; 2002 Mar; 99(6):3854-9. PubMed ID: 11891278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cell surface expression of CD25, CD54, and CD95 on B- and T-cells in chronic lymphocytic leukaemia in relation to trisomy 12, atypical morphology and clinical course.
    Hjalmar V; Hast R; Kimby E
    Eur J Haematol; 2002 Mar; 68(3):127-34. PubMed ID: 12068792
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of the CD40 and CD95 (APO-1/Fas) antigens in the apoptosis of human B-cell malignancies.
    Wang D; Freeman GJ; Levine H; Ritz J; Robertson MJ
    Br J Haematol; 1997 May; 97(2):409-17. PubMed ID: 9163608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resistance to CD95-mediated apoptosis of CD40-activated chronic lymphocytic leukemia B cells is not related to lack of DISC molecules expression.
    de Totero D; Montera M; Rosso O; Clavio M; Balleari E; Foa R; Gobbi M
    Hematol J; 2004; 5(2):152-60. PubMed ID: 15048066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Caspase 8 activation independent of Fas (CD95/APO-1) signaling may mediate killing of B-chronic lymphocytic leukemia cells by cytotoxic drugs or gamma radiation.
    Jones DT; Ganeshaguru K; Virchis AE; Folarin NI; Lowdell MW; Mehta AB; Prentice HG; Hoffbrand AV; Wickremasinghe RG
    Blood; 2001 Nov; 98(9):2800-7. PubMed ID: 11675354
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Qualitative and quantitative characterization of Fas (APO-1/CD95) on leukemic cells derived from patients with B-cell neoplasms.
    Tsuruda K; Yamada Y; Hirakata Y; Sugahara K; Maeda T; Atogami S; Tomonaga M; Kamihira S
    Leuk Res; 1999 Feb; 23(2):159-66. PubMed ID: 10071131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. On the role and significance of Fas (Apo-1/CD95) ligand (FasL) expression in immune privileged tissues and cancer cells using multiple myeloma as a model.
    Greil R; Egle A; Villunger A
    Leuk Lymphoma; 1998 Nov; 31(5-6):477-90. PubMed ID: 9922038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative characterization and potential function of membrane Fas/APO-1 (CD95) receptors on leukaemic cells from chronic B and T lymphoid leukaemias.
    Kamihira S; Yamada Y; Hirakata Y; Tsuruda K; Sugahara K; Tomonaga M; Maeda T; Tsukasaki K; Atogami S; Kobayashi N
    Br J Haematol; 1997 Dec; 99(4):858-65. PubMed ID: 9432034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. fas-mediated lysis of chronic lymphocytic leukaemia cells: role of type I versus type II cytokines and autologous fasL-expressing T cells.
    Williams JF; Petrus MJ; Wright JA; Husebekk A; Fellowes V; Read EJ; Gress RE; Fowler DH
    Br J Haematol; 1999 Oct; 107(1):99-105. PubMed ID: 10520029
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Constitutive caspase activation and impaired death-inducing signaling complex formation in CD95-resistant, long-term activated, antigen-specific T cells.
    Strauss G; Knape I; Melzner I; Debatin KM
    J Immunol; 2003 Aug; 171(3):1172-82. PubMed ID: 12874203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic lymphocytic leukemia B cells inhibit spontaneous Ig production by autologous bone marrow cells: role of CD95-CD95L interaction.
    Sampalo A; Navas G; Medina F; Segundo C; Cámara C; Brieva JA
    Blood; 2000 Nov; 96(9):3168-74. PubMed ID: 11049999
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Defective expression of the apoptosis-inducing CD95 (Fas/APO-1) molecule on T and B cells in IDDM.
    Giordano C; De Maria R; Stassi G; Todaro M; Richiusa P; Giordano M; Testi R; Galluzzo A
    Diabetologia; 1995 Dec; 38(12):1449-54. PubMed ID: 8786019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between the expression of CD25 and CD69 on the surface of lymphocytes T and B from peripheral blood and bone marrow of patients with chronic lymphocytic leukemia and established prognostic factors of this disease.
    Grywalska E; Bartkowiak-Emeryk M; Pasiarski M; Olszewska-Bożek K; Mielnik M; Podgajna M; Pieczykolan M; Hymos A; Fitas E; Surdacka A; Góźdź S; Roliński J
    Adv Clin Exp Med; 2018 Jul; 27(7):987-999. PubMed ID: 29893517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage.
    Galle PR; Hofmann WJ; Walczak H; Schaller H; Otto G; Stremmel W; Krammer PH; Runkel L
    J Exp Med; 1995 Nov; 182(5):1223-30. PubMed ID: 7595193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression and function of the FAS antigen in B chronic lymphocytic leukemia and hairy cell leukemia.
    Panayiotidis P; Ganeshaguru K; Foroni L; Hoffbrand AV
    Leukemia; 1995 Jul; 9(7):1227-32. PubMed ID: 7543175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.